×
TMO is the ticker for Thermo Fisher Scientific Inc., one of the world's largest providers of scientific instruments, laboratory supplies, diagnostics, and services to the life sciences and healthcare industries. The company was formed in 2006 through the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, Massachusetts.
ARDX (Ardelyx) is a commercial-stage biopharmaceutical company, while VCYT (Veracyte) is a genomics-based cancer diagnostics company — two very different healthcare business models. Both stocks have traded near their 52-week lows in recent weeks, but for different reasons: litigation and payer-access pressure for ARDX , and a growth reset for its flagship test at VCYT .
Quest Diagnostics and Labcorp are the two largest independent clinical laboratories in the United States, making this a direct comparison of market leaders within the same diagnostics sector. DGX is delivering faster organic test-volume growth and higher operating margins, while LH commands a larger revenue base and a more diversified business model.
Guardant Health shares fell from a $153.43 prior close to $145.32, down -5.29%, during regular trading, extending an after-hours slide. The drop followed Q3 results released after the November 5 close: revenue and adjusted EPS beat, but the company raised 2026 free cash flow burn guidance to $205–$220 million, disappointing investors.
WGS shares slid -5.83% to $60.61 from a prior close of $64.36, with the decline unfolding during regular market hours. No verified news or fundamental catalyst found. The drop is consistent with the stock's habit of large swings — it averaged a roughly 3.9% absolute daily move over the prior 60 sessions and posted 13 moves of at least 5.83% — as it trades into its November 9 Q3 report.
Castle Biosciences shares slid from a $34.20 prior close to $32.42, down -5.20%, during regular trading on Nov 6. The decline follows Q3 results released after the Nov 5 close: EPS of -$0.13 beat the -$0.35 estimate and revenue of $102.9M topped $92.4M, with FY 2026 guidance raised to $385M-$395M — yet shares fell in a sell-the-news reaction as investors weighed a wider net loss, slower DecisionDx-Melanoma growth and a CMS gap-fill proposal for AdvanceAD-Tx.
FRNM fell from a previous close of $10.47 to $9.93, a drop of -5.16%, during regular market hours. No verified news or fundamental catalyst found. The decline is likely consistent with continued selling in this newly public, de-SPAC'd micro-cap biotech, which has a typical daily move of about 3.3% and has slid from its mid-October peak near $17.50.
XGN dropped from a $7.60 prior close to $6.34, a -16.58% decline, during regular market hours on November 6. No verified news or fundamental catalyst found. The move likely reflects continued profit-taking in this low-float micro-cap after its run from roughly $6.6 in August to $8.7 in late October, compounded by broad small-cap diagnostics weakness.
Biodesix (BDSX) shares cratered from Thursday's $19.84 close to about $9.50, a -52.12% drop, with the decline running through Thursday's after-hours session and Friday's regular trading. The selloff followed Q3 results: revenue of $24.0M missed the ~$27.5M consensus, and management slashed full-year 2026 revenue guidance to $101M–$103M from a prior $108M–$114M, snapping a beat-and-raise streak.
FLGT jumped +18.38% during regular market hours, climbing from a previous close of $18.66 to $22.09. The gain followed the Q3 earnings beat released after the Nov. 5 close: non-GAAP EPS of -$0.09 versus roughly -$0.65 expected and revenue of $90.4M versus $86.3M, with improved full-year loss guidance.
BNR slipped during the regular session, easing from a prior close of $13.25 to $12.85, a decline of -3.02%. No verified news or fundamental catalyst found. The pullback is consistent with ordinary choppy trading in this low-priced, thinly-traded micro-cap, which has averaged roughly ±6% daily moves over the last 60 sessions.
NTRA fell from a prior close of $363.76 to $325.40, a -10.55% decline, during regular trading Friday, extending losses that began in after-hours following Thursday's earnings. The drop followed Q3 results released after Thursday's close: a wider-than-expected loss of $0.42/share versus $0.28 expected, raised spending guidance, and a surprise CEO transition as Steve Chapman stepped down for Solomon Moshkevich — overshadowing a 34% revenue beat and a raised full-year outlook.
BDSX plummeted -40.78%, sliding from a prior close of $19.84 to $11.75, with the decline unfolding largely in premarket trading. The selloff followed Q3 results reported after Thursday's close: revenue of $24.0 million missed estimates near $27.5 million, and management cut full-year 2026 revenue guidance to $101M-$103M from $108M-$114M.
Guardant Health shares fell during regular trading, dropping from Thursday's close of $153.43 to about $144.80 intraday — a decline of -5.62%. The move extends the reaction to Q3 2026 results reported after Thursday's close: EPS of -$0.29 and revenue of $361M (+36% YoY) beat estimates and full-year revenue guidance was raised, but full-year free cash flow burn guidance was raised to $205M–$220M, disappointing investors.
Natera (NTRA) fell -14.14% to $312.32 from a $363.76 prior close, with the selloff beginning after Thursday's close and carrying through premarket into Friday's regular session. Third-quarter results and an abrupt CEO transition drove the drop: a GAAP loss of -$0.42/share missed the -$0.27 consensus, and CEO Steve Chapman stepped down, replaced by Solomon Moshkevich.
Biodesix reported third-quarter 2025 revenue of $21.8 million , up 20% year over year and ahead of the roughly $21.0 million consensus estimate. Gross margin expanded to 81% , a 400-basis-point improvement from 77% in the prior-year period, driven by cost reductions per test.
Fulgent Genetics reported third quarter 2026 revenue of $90.4 million , ahead of the $86.3 million consensus estimate. Non-GAAP (non-Generally Accepted Accounting Principles) loss per share came in at $0.09 , significantly better than the $0.65 consensus loss and the prior quarter's $0.58 loss.
Castle Biosciences reported third quarter 2026 revenue of $102.9 million , up 24% year over year and ahead of consensus estimates of roughly $92 million. Diluted net loss per share was $0.13 , narrower than the consensus expectation of a roughly $0.35–$0.38 loss per share.
Guardant Health reported third-quarter 2026 revenue of $361 million, up 36% year over year and above the consensus estimate of roughly $351 million. Adjusted (non-GAAP) net loss narrowed to $0.29 per share, better than the consensus estimate of about $0.31 per share.
Natera reported third quarter 2026 total revenue of $794.0 million , up 34.1% from $592.2 million in the prior-year period. The net loss narrowed to $59.9 million , or $0.42 per share, versus a loss of $87.5 million, or $0.64 per share, a year earlier.